VENTOLIN
LOE ApproachingNDAINHALATIONSOLUTION
Approved
Apr 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
VENTOLIN by GSK is 2 -adrenergic receptors compared with isoproterenol. Approved for exercise-induced bronchospasm in adult, older. First approved in 1992.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VENTOLIN is a branded inhalation solution approved by GSK in 1992 for respiratory indications. The product is formulated as an inhaled solution representing a small-molecule therapeutic approach. Specific mechanism of action and indications are not disclosed in available data.
LOE Approaching
With LOE approaching and moderate competitive pressure (30 competitive index), the brand team is likely in transition or optimization mode with potentially constrained headcount.
Mechanism of Action
2 -adrenergic receptors compared with isoproterenol. Although beta 2 -adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1 -adrenoceptors are the predominant receptors in the heart, there are also beta 2 -adrenoceptors in the human heart comprising 10% to 50%…
Indications (2)
Worked on VENTOLIN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.